Researchers at Moffitt Cancer Center focused on a form of cell death called necroptosis. Previously thought to help the ...

Biologic therapies are revolutionising severe asthma management, showcasing potential for remission, but cost and equitable ...

FDA Project Team supports the company's proposed Phase 3 trial strategy, including overall trial design, target patient population, treatment schedule, and primary endpoint Final Protocol submission ...

MDNA11 shows significant survival benefits in preclinical glioblastoma models, expanding CD8+ T and NK cells Bizaxofusp selectively targets human tumor cells and immune-suppressive cells, enhancing ...

A daily dose of vitamin B3 reduced inflammation in the lungs of patients with COPD, Danish researchers report.  "This is ...

Oral peptide with biologics-like high potency and spectrum of activity against three therapeutically relevant dimeric forms of IL-17 (AA, AF and FF) IND enabling studies underway, with Phase I ...

Type 2 diabetes (T2D) and obesity (OB) are associated with chronic low-grade inflammation and increased fracture risk. In vitro studies showed that inflammation induces bone erosion and inhibits bone ...

Interleukin-1 receptor-associated kinase 4 is critical in the modulation of inflammatory responses through Toll-like receptor and IL-1R signaling.

The US Food and Drug Administration has approved bimekizumab, a humanized interleukin (IL)-17A and IL-17F antagonist, for the ...

Treatment with IV secukinumab led to rapid improvements in the signs and symptoms of PsA, which were maintained through 52 weeks.

A trio of abstracts presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, bear out the benefits of bimekizumab (Bimzelx; UCB Pharma) for use against active ...